TargetBeta
PRAME
PRAME nuclear receptor transcriptional regulator · also CT130, MAPE · PRAME family
3 programs in company-led studies act on PRAME, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| anzutresgene autoleucelrule | Immatics US | phase 3 | 33 running | – | NCIt |
| Autologous Anti-PRAME TCR-expressing T-cells OPB-201rule | Outpace Bio | phase 1 | 11 running | – | NCIt |
| PRAME mRNA Vaccine mRNA-4203rule | Immatics US | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Melanoma, 2 programs
- Endometrial Neoplasms, 1 program
- Melanoma, Cutaneous Malignant, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 2028anzutresgene autoleucel · Immatics US · phase 3 · NCT06743126
- Aug 2029PRAME mRNA Vaccine mRNA-4203 · Immatics US · phase 1 · NCT06946225
- Jun 2030Autologous Anti-PRAME TCR-expressing T-cells OPB-201 · Outpace Bio · phase 1 · NCT07664735
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.